Andrew Gengos Terns Pharmaceuticals, Inc. (TERN) insider trading activity

TERN Quotes by TradingView

Andrew Gengos is Chief Financial Officer of Terns Pharmaceuticals, Inc.. Currently has a direct ownership of 101,788 shares of TERN, which is worth approximately $2.29 Million. The most recent transaction as insider was on Jan 14, 2026, when has been sold 68,750 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 102K
307.15% 3M change
n/a 12M change
Total Value Held $2.29 Million

Andrew Gengos Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 14 2026
BUY
Grant, award, or other acquisition
-
68,750 Added 40.31%
101,788 Common Stock
Jun 27 2025
BUY
Open market or private purchase
$39,300 $3.93 p/Share
10,000 Added 28.57%
25,000 Common Stock
Jun 16 2025
BUY
Open market or private purchase
$19,750 $3.95 p/Share
5,000 Added 25.0%
15,000 Common Stock
Jun 13 2025
BUY
Open market or private purchase
$37,400 $3.74 p/Share
10,000 Added 50.0%
10,000 Common Stock

Also insider at

CYT
Cyteir Therapeutics, Inc. Healthcare
Chief Business Officer
ATHA
Athira Pharma, Inc. Healthcare
CFO and Chief Business Officer
TTRX
Turn Therapeutics Inc.
Director
AG

Andrew Gengos

Chief Financial Officer
Lexington, MA

Track Institutional and Insider Activities on TERN

Follow Terns Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TERN shares.

Notify only if

Insider Trading

Get notified when an Terns Pharmaceuticals, Inc. insider buys or sells TERN shares.

Notify only if

News

Receive news related to Terns Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on TERN